Updates are available Correction dated 2019-08-05
Click to view Correction: https://doi.org/10.1186/s40478-019-0780-9
-
Authors
Harrison, Ian F. http://orcid.org/0000-0003-1250-4911
Whitaker, Rozalind
Bertelli, Pietro Maria
O’Callaghan, James M.
Csincsik, Lajos
Bocchetta, Martina
Ma, Da
Fisher, Alice
Ahmed, Zeshan
Murray, Tracey K.
O’Neill, Michael J.
Rohrer, Jonathan D.
Lythgoe, Mark F.
Lengyel, Imre
-
Funding
Funding for this research was provided by:
Engineering and Physical Sciences Research Council (EP/N034864/1)
Medical Research Council (MR/J500422/1, MR/M008525/1)
Eli Lilly and Company
NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH)
Bill Brown Charitable Trust
- License Information
-
More Information
Article History
Received: 13 December 2018
Accepted: 20 December 2018
First Online: 7 January 2019
Change Date: 5 August 2019
Change Type: Correction
Change Details: In the original publication of this article [1], the funding acknowledgement for grant “<b>Alzheimer Society Research Program (ASRP) from the Alzheimer Society of Canada</b>” was missing.
Ethics approval and consent to participate
: For human data, the study was approved by the local ethics committee (Queen Square Neurology Research Ethics Committee) and written informed consent was obtained from all participants. For animal data, all the experiments were performed in accordance with the Animals (Scientific Procedures) Act 1986 (ASPA) revised according to the European Directive 2010/63/EU and the UK Home Office (Scientific Procedures) Act (1986) with prior project approval from UCL’s internal Animal Welfare and Ethical Review Body.
: Not applicable.
: AF, ZA, TKM and MJO’N are all/were full time employees of Eli Lilly and Company.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
